LONDON – Evotec AG is bolstering its coffers by €90.3 million (US$96.1 million) in a private placing of new shares with Novo A/S, and plans to invest the funds to further develop its induced pluripotent stem cell (iPSC) platform, pursue M&A opportunities and provide long-term support to its early stage drug discovery partnerships.